劉建軍,男,主任醫(yī)師,科室主任,一直從事核醫(yī)學(xué)SPECT/CT、PET/CT影像診斷與核素碘-131治療工作,在碘-131治療甲狀腺功能亢進(jìn)疾病具有豐富經(jīng)驗(yàn)。學(xué)術(shù)職務(wù):中華核醫(yī)學(xué)會(huì)全國(guó)委員;上海市核醫(yī)學(xué)專委會(huì)委員;中國(guó)醫(yī)師協(xié)會(huì)核醫(yī)學(xué)分會(huì)定期考核委員會(huì)委員;中國(guó)生物物理學(xué)會(huì)分子影像專委會(huì)全國(guó)委員;《中華核醫(yī)學(xué)雜志》通信編委;《國(guó)際放射醫(yī)學(xué)與核醫(yī)學(xué)》編委。主持國(guó)家自然基金面上項(xiàng)目1項(xiàng)獲得榮譽(yù)1. 2011年度衛(wèi)生部華夏科技獎(jiǎng)一等獎(jiǎng):正電子發(fā)射斷層顯像技術(shù)的臨床轉(zhuǎn)化研究與國(guó)產(chǎn)化應(yīng)用。(第3完成人)2. 2010年度上海市科技進(jìn)步二等獎(jiǎng):正電子發(fā)射斷層顯像技術(shù)的臨床轉(zhuǎn)化研究與國(guó)產(chǎn)化應(yīng)用。(第3完成人)3. 2009年度中華醫(yī)學(xué)科技三等獎(jiǎng)?wù)娮影l(fā)射斷層顯像的方法學(xué)優(yōu)化與國(guó)產(chǎn)化應(yīng)用策略。(第3完成人)4. 2009年度上海市醫(yī)學(xué)科技三等獎(jiǎng)::18F-FDG PET/CT的方法學(xué)優(yōu)化及臨床應(yīng)用策略(第3完成人)論文著作1) Zhang H, Gu C, Yu J, Wang Z, Yuan X, Yang L, Wang J, Jia Y, Liu J*, Liu F*,Radiosensitization of glioma cells by TP53 induced glycolysis and apoptosis regulator knockdown is dependent on thioredoxin-1 nuclear translocation, Free Radic Biol Med, 69C:239-248, 2014(共同通訊作者,IF:5.271)2) Yu Z, Zhao X, Ge Y, Zhang T, Huang L, Zhou X, Xie L, Liu J*, Huang G*, A Regulatory Feedback Loop between HIF-1α and PIM2 in HepG2 Cells, PLoS One, 5;9(2):e88301,2014(共同通訊作者,IF:3.73)3) Zhou X, Xie W, Li Q, Zhang Y, Zhang J, Zhao X, Liu J*, Huang G*, TIGAR is correlated with maximal standardized uptake value on FDG-PET and survival in non-small cell lung cancer, PLoS One, 10;8(12):e80576,2013(共同通訊作者, IF:3.73)4) Yu Z, Zhao X, Huang L, Zhang T, Yang F, Xie L, Song S, Miao P, Zhao L, Sun X, Liu J*, Huang G*, Proviral insertion in murine lymphomas 2 (PIM2) oncogene phosphorylates pyruvate kinase M2 (PKM2) and promotes glycolysis in cancer cells,J Biol Chem,288(49):35406-16,2013(共同通訊作者,IF:4.651)5) Sheng SL#, Liu JJ#, Dai YH, Sun XG, Xiong XP, Huang G*, Knockdown of lactate dehydrogenase A suppresses tumor growth and metastasis of human hepatocellular carcinoma, FEBS J, 279(20):3898-910,2012(共同第一作者,IF:4.25)6) Xue H#, Liu J#, Lin B, Wang Z, Sun J, Huang G*,A meta-analysis of interleukin-8 -251 promoter polymorphism associated with gastric cancer risk,PLoS One,7(1):e28083, 2012(共同第一作者,IF:3.73)7) Zhang C#, Liu J#, Tong J, Sun X, Song S, Huang G*,18F-FDG-PET evaluation of pathological tumour response to neoadjuvant therapy in patients with NSCLC, Nucl Med Commun,279(20):3898-910,2012(共同第一作者,IF:1.3...
詳情